Dr. Faust is a pioneer in this research and was the first to CpG-deplete AAV vectors to circumvent TLR9 activation, a technology that has become an industry standard.
February 14th, 2023 - Read Dr. Faust’s Journal of Clinical Investigation scientific publication from 2013 demonstrating that CpG-depleted AAV vectors can establish persistent transgene expression, evade immunity, and minimize infiltration of effector cells following gene transfer.
